ENHANCED PROVIDES CLINICAL TRIAL UPDATE - FIRST OF ITS KIND STUDY CONTINUES WITH ATHLETES HEALTHY & SAFE TO COMPETE
Enhanced Group announced that the interventional phase of its ASCEND001 clinical trial has concluded, with the five-year observational monitoring period now commencing. The study, posted to ClinicalTrials.gov, covered 36 of the 42 athletes competing in the upcoming Enhanced Games, confirming they are healthy and safe to compete. Aggregate data revealed high usage of performance-enhancing substances among participants, including 91% using testosterone and 79% using human growth hormone, all under medical supervision.
Key figures
- Epo usage pct
- 41%
- Hgh usage pct
- 79%
- Athletes in trial
- 36
- Stimulant usage pct
- 62%
- Testosterone usage pct
- 91%
- Total athletes competing
- 42
- Anabolic steroid usage pct
- 29%
- Hormonal support usage pct
- 5%
- Metabolic modulator usage pct
- 50%
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.